NCT00426530View on ClinicalTrials.gov

Safety of Everolimus in Combination Therapy, in Patients With HER2-overexpressing Metastatic Breast Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2010

Conditions
Breast NeoplasmsNeoplasm Metastasis
Interventions
DRUG

everolimus (RAD001)

Trial Locations (6)

1000

Novartis Investigative Site, Brussels

4000

Novartis Investigative Site, Liège

20133

Novartis Investigative Site, Milan

75231

Novartis Investigative Site, Paris

02-781

Novartis Investigative Site, Warsaw

SE-171 76

Novartis Investigative Site, Stockholm

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY